Consumer-Led Screening for Atrial Fibrillation

Guo, Yutao; Zhang, Hui; Lip, Gregory Y.H.

doi:10.1016/j.jacasi.2022.07.006

Cited by 7 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four hundred and fifty subjects returned their ECG patch with analyzable data, and in the 86 participants who received an IRN during concurrent use of the ECG patch, 72 had AF detected with the ECG patch resulting in a PPV was 0.84. A similar large scale study conducted on the Fitbit irregular heart rhythm detection feature resulted in a PPV of 98.2%, 5 and the Huawei Heart Study reported a PPV of 91.6% 6 …”

Section: Discussionmentioning

confidence: 81%

“…A similar large scale study conducted on the Fitbit irregular heart rhythm detection feature resulted in a PPV of 98.2%, 5 and the Huawei Heart Study reported a PPV of 91.6%. 6 While these data support the FDA-labeled indication of the IRN in a screening population without known AF, IRN is increasingly being used for management of patients with an existing history of AF. A prior study by our group assessed the accuracy of a different AF sensing watch compared to simultaneous recordings from an ICM.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Accuracy of the Apple watch for detection of AF: A multicenter experience

Wasserlauf

Vogel

Whisler

et al. 2023

Cardiovasc electrophysiol

View full text Add to dashboard Cite

Introduction:The Apple watch (AW) irregular rhythm notification (IRN) feature uses photoplethysmography to identify prolonged episodes of irregular rhythm suggestive of atrial fibrillation (AF). IRN is FDA cleared for those with no previous history of AF, however, these devices are increasingly being used for AF management. The objective of the present study was to determine the accuracy of the IRN in subjects with a previous diagnosis of nonpermanent AF.Methods: Subjects with a history of nonpermanent AF and either an insertable cardiac monitor (ICM) or cardiac implanted electronic device (CIED) with <5% ventricular pacing were fitted with an AW Series 5 for 6 months. AF episodes were compared between the ICM/CIED and IRN. The primary endpoints were sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the IRN by subject for AF ≥1 h. Secondary endpoints were sensitivity and PPV by AF episode ≥1 h. Analysis was limited to a maximum of 10 ICM/CIED episodes per subject and included only those AF episodes occurring during active AW use confirmed by activity data.Results: Thirty participants were enrolled. Mean age was 65.4 ± 12.2 years and 40% were female. There were 10 ICMs and 20 CIEDs. Eleven subjects had AF on ICM/ CIED while the AW was worn, of whom 8 were detected by IRN. There were no false positive IRN detections by subject ("by subject" 72% sensitivity, 100% specificity, 100% PPV, and 90% NPV). Five subjects had AF only when the AW was not worn. There were a total of 70 AF episodes on ICM/CIED, 35 of which occurred while the AW was being worn. Of these, 21 were detected by IRN with 1 false positive ("by episode" sensitivity = 60.0%, PPV = 95.5%). Conclusion:In a population with known AF, the AW IRN had a low rate of false positive detections and high specificity.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 95%

Accuracy of the Apple watch for detection of AF: A multicenter experience

Wasserlauf

Vogel

Whisler

et al. 2023

Cardiovasc electrophysiol

View full text Add to dashboard Cite

show abstract

“…22 With the use of validated wearables, a consumer-led screening approach can be applied for the detection of AF 23 and its susceptible risk factors. 24 Screening for AF with validated wearables in the elderly, 25 or the high-risk population, such as with OSA, hypertension, diabetes, and post-stroke, will facilitate the early detection and management of AF.…”

Section: Af Screeningmentioning

confidence: 99%

“…22 With the use of validated wearables, a consumer-led screening approach can be applied for the detection of AF 23 and its susceptible risk factors. 24…”

Section: Af Screeningmentioning

confidence: 99%

2024 Chinese Expert Consensus Guidelines on the Diagnosis and Treatment of Atrial Fibrillation in the Elderly, Endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): Executive Summary

Wang,

Guo,

Qin

et al. 2024

Thromb Haemost

View full text Add to dashboard Cite

The consensus guidelines of the Geriatric Society of Chinese Medical Association (GSCMA) on the management of atrial fibrillation (AF) in the elderly was first published in 2011 and updated in 2016, with endorsement by Chinese Society of Geriatric Health Medicine (CSGHM). Since then, many important studies regarding the screening and treatment in the elderly population have been reported, necessitating this updated expert consensus guidelines. The writing committee members comprehensively reviewed updated evidence pertaining to elderly patients with AF, and formulated this 2024 update. The highlighted issues focused on the following: screening for AF, geriatric comprehensive assessment, use of the Atrial fibrillation Better Care (ABC) pathway for the elderly patients, and special clinical settings related to elderly patients with AF. New recommendations addressing smart technology facilitated AF screening, ABC pathway based management and optimal anticoagulation were developed, with a focus on the elderly.

show abstract

“…While smartwatches may improve detection of atrial fibrillation (AF), including asymptomatic AF, previous studies have reported high false positive rates. The mAF-App II trial, which used Huawei smartwatch photoplethysmography, reported data from 2.8 million people in China who downloaded the app [66]. During 4 years follow-up, 12,244 (0.4%) people received a query AF notification, 5,227 attended for clinical evaluation with ECG and 24-h Holter monitoring and, within this group, AF was confirmed in 93.8%.…”

Section: Atrial Fibrillationmentioning

confidence: 99%

Advances in Clinical Cardiology 2022: A Summary of Key Clinical Trials

et al. 2023

View full text Add to dashboard Cite

Introduction: Over the course of 2022, numerous key clinical trials with valuable contributions to clinical cardiology were published or presented at major international conferences. This review seeks to summarise these trials and to reflect on their clinical context. Methods: The authors reviewed clinical trials presented at major cardiology conferences during 2022, including the American College of Cardiology (ACC), European Association for Percutaneous Cardiovascular Interventions (EuroPCR), European Society of Cardiology (ESC), Transcatheter Cardiovascular Therapeutics (TCT), American Heart Association (AHA), European Heart Rhythm Association (EHRA), Society for Cardiovascular Angiography and Interventions (SCAI), TVT-The Heart Summit (TVT) and Cardiovascular Research Technologies (CRT). Trials with a broad relevance to the cardiology community and those with potential to change current practice were included. Results: A total of 93 key cardiology clinical trials were identified for inclusion. Interventional cardiology data included trials evaluating the use of new generation novel stent technology and new intravascular physiology strategies such as quantitative flow ratio (QFR) to guide revascularisation in stable and unstable coronary artery disease. New trials in acute coronary syndromes and intervention focused on long-term outcomes of optimal medical therapy (OMT), revascularisation in ischaemic dysfunction and left main (LM) intervention. Structural intervention trials included latest data on optimal timing and anticoagulation strategies in transcatheter aortic valve replacement (TAVR), in addition to expanding evidence in mitral and tricuspid valve interventions. Heart failure data included trials with sodium-glucose cotransporter 2 (SGLT2) inhibitors, iron replacement and novel drugs such as omecamtiv. Prevention trials included new data on proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and polypill strategies. In electrophysiology, new data regarding optimal timing of ablative therapy for atrial fibrillation (AF) in addition to novel screening strategies were evaluated. Conclusion: This article presents a summary of key clinical cardiology trials published and presented during the past year and should be of interest to both practising clinicians and researchers.

show abstract

Consumer-Led Screening for Atrial Fibrillation

Cited by 7 publications

References 25 publications

Accuracy of the Apple watch for detection of AF: A multicenter experience

Accuracy of the Apple watch for detection of AF: A multicenter experience

2024 Chinese Expert Consensus Guidelines on the Diagnosis and Treatment of Atrial Fibrillation in the Elderly, Endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): Executive Summary

Advances in Clinical Cardiology 2022: A Summary of Key Clinical Trials

Contact Info

Product

Resources

About